Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Kiniksa Pharmaceuticals International, plc

NASDAQ: KNSA · Life Sciences · 10 alerts · CIK 1730430

Share price
$94.23Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kiniksa Pharmaceuticals International, plc filings on SEC EDGAR ↗

4:34 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International CAO Michael R. Megna Sells $1.11M of Stock

Michael R. Megna, CAO, sold 11,280 shares of Kiniksa Pharmaceuticals International, plc at $98.54 a share, worth $1.11M in total on Nov 9, 2026. Shares held after the trade: 12,697 (-47.0%).

Value
$1.11M
Shares
11,280
Price
$98.54
Role
CAO
Holding change
-47.0%
Trade date
Nov 9, 2026
4:52 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International Chairman & CEO Sanj K. Patel Sells $14.3M of Stock

Sanj K. Patel, Chairman & CEO, sold 151,300 shares of Kiniksa Pharmaceuticals International, plc at $92.35 to $96.05 a share (average $94.71) in 5 transactions, worth $14.3M in total on Nov 4, 2026. Shares held after the trade: 774,500 (-3.4%).

Value
$14.3M
Shares
151,300
Average price
$94.71
Role
Chairman & CEO
Holding change
-3.4%
Trade date
Nov 4, 2026
7:30 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International Chairman & CEO Sanj K. Patel Sells $37.4M of Stock

Sanj K. Patel, Chairman & CEO, sold 402,394 shares of Kiniksa Pharmaceuticals International, plc at $90.77 to $98.16 a share (average $92.92) in 14 transactions, worth $37.4M in total between Oct 30, 2026 and Nov 3, 2026. Shares held after the trade: 780,037 (-0.6%).

Value
$37.4M
Shares
402,394
Average price
$92.92
Role
Chairman & CEO
Holding change
-0.6%
Trade date
Oct 30, 2026 to Nov 3, 2026
6:33 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International CFO Mark Ragosa Sells $3.39M of Stock

Mark Ragosa, CFO, sold 36,783 shares of Kiniksa Pharmaceuticals International, plc at $91.40 to $94.01 a share (average $92.16) in 4 transactions, worth $3.39M in total on Nov 2, 2026. Shares held after the trade: 20,854 (-1.0%).

Value
$3.39M
Shares
36,783
Average price
$92.16
Role
CFO
Holding change
-1.0%
Trade date
Nov 2, 2026
6:29 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International CMO John F. Paolini Sells $8.94M of Stock

John F. Paolini, CMO, sold 96,000 shares of Kiniksa Pharmaceuticals International, plc at $92.02 to $97.77 a share (average $93.09) in 10 transactions, worth $8.94M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 69,922 (-1.0%).

Value
$8.94M
Shares
96,000
Average price
$93.09
Role
CMO
Holding change
-1.0%
Trade date
Oct 30, 2026 to Nov 2, 2026
6:27 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International COO Ross Moat Sells $9.63M of Stock

Ross Moat, COO, sold 103,585 shares of Kiniksa Pharmaceuticals International, plc at $91.23 to $97.76 a share (average $92.93) in 11 transactions, worth $9.63M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 10,294 (-6.6%).

Value
$9.63M
Shares
103,585
Average price
$92.93
Role
COO
Holding change
-6.6%
Trade date
Oct 30, 2026 to Nov 2, 2026
6:26 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International CAO Michael R. Megna Sells $3.42M of Stock

Michael R. Megna, CAO, sold 36,260 shares of Kiniksa Pharmaceuticals International, plc at $91.87 to $97.74 a share (average $94.43) in 7 transactions, worth $3.42M in total on Oct 30, 2026. Shares held after the trade: 12,697 (-29.6%).

Value
$3.42M
Shares
36,260
Average price
$94.43
Role
CAO
Holding change
-29.6%
Trade date
Oct 30, 2026
4:36 PM ET 10-Q
Financial Results

Kiniksa Pharmaceuticals International Q3 2026 Results: Net Income $47.3M, Up 156.8% YoY

Kiniksa Pharmaceuticals reported total product revenue of $285.97 million for the third quarter of 2026, a significant increase from $180.86 million in the prior year. Net income for the quarter rose to $47.35 million, while the company maintained a strong liquidity position with $568.76 million in cash, cash equivalents, and short-term investments.

Key figure
Net income $47.3M · +156.8% YoY
7:33 AM ET 8-K
Financial Results

Kiniksa Pharmaceuticals International Financial Results

Kiniksa Pharmaceuticals reported Q3 2026 financial results, highlighted by ARCALYST net product revenue of $286.0 million, a 58% year-over-year increase. The company raised its full-year 2026 ARCALYST net product revenue guidance to a range of $1.045 billion to $1.050 billion.

“Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis. In the third quarter, strong commercial execution led to gains in patient and physician adoption, resulting in revenue of $286.0 million and positioning ARCALYST to achieve blockbuster status this year”

Sanj K. Patel, Chairman & Chief Executive Officer of Kiniksa
4:29 PM ET 8-K
Executive Compensation

Kiniksa Pharmaceuticals International Executive Compensation

Kiniksa Pharmaceuticals appointed Ross Moat as President and Chief Operating Officer, effective immediately. The company also approved an increase in Moat's annual base salary to $700,000 and his annual target bonus to 60%, effective January 1, 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.